Aurealis Therapeutics Completes Patient Recruitment in DIAMEND Phase 2 Diabetic Foot Ulcer Clinical Trial of AUP-16
Aurealis Therapeutics, a clinical-stage Swiss-Finnish company developing multi-target cell and gene therapies for chronic wounds and cancer, announced today the successful completion of patient recruitment in its DIAMEND AUP-16 Phase-2 clinical trial on Diabetic Foot Ulcers (DFUs). This achievement is an important milestone in the evaluation of AUP-16’s potential to address the unmet medical needs […]
